Latest news

• Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

  Sanofi is already involved in this therapy area – in March 2020, the US Food and Drug Administration approved its multiple myeloma treatment Sarclisa (isatuximab). ... The FDA approved Sarclisa for the treatment of patients with relapsed or refractor

• J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

  The new data bolsters Darzalex’s position in the multiple myeloma, where it faces competition from Sanofi’s cancer treatment Sarclisa (isatuximab-irfc). ... Like Darzalex, Sarclisa is designed to target the CD38 protein found on the surface of

• Second Sarclisa combination regimen for multiple myeloma approved in EU

  Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment. ... That makes the later line drugs, such as Sarclisa, important for those patient who have exhausted other options.

• Sanofi reports a profit in Q4 as Dupixent sales climb

  Oncology sales were also up in Q4 2020, growing 24.6% to 213m – driven primarily by new launches of multiple myeloma treatment Sarclisa (isatuximab) and skin cancer therapy Libtayo (cemiplimab).

• Sanofi set to acquire Kiadis for €308m

  Sanofi licensed Kiadis’ pre-clinical K-NK004 programme for multiple myeloma in July, to use in combination with its CD38 inhibitor, Sarclisa.